Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Coherus BioSciences, Inc.

Coherus BioSciences develops immuno-oncology therapies aimed at cancer treatment, including FDA-approved medicines such as LOQTORZI. It focuses on improving patient outcomes through a diversified pipeline of drug candidates.

NASDAQ:CHRS

Coherus BioSciences

1.05

+1.94%

0.03

Last Close

1.02

12/05 22:30

Market Cap

121.72M

Beta: 0.95

Volume Today

1.14M

Avg: 1.01M

PE Ratio

−0.89

PFCF: −0.86

name

homepage url

country

employee count

sector

industry

revenue

Description

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics